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Summary

Background
The World Health Organization (WHO) classification of brain tumors describes 15 subtypes of meningioma. Nine of these are allotted to WHO grade I, and three each to grade II and grade III, respectively. Grading is purely based on histology, with molecular markers lacking. While the current classification and grading approach is of prognostic value, it harbors shortcomings such as ill-defined parameters for subtypes and grading criteria prone to arbitrary judgment.
Methods
We investigated genome-wide DNA methylation patterns of 479 meningiomas to identify distinct methylation classes (MC) of meningioma. The MCs were further characterized by DNA copy-number analysis, mutational profiling and RNA sequencing. We validated our findings in an independent cohort of 140 tumors. Interpretation DNA methylation-based meningioma classification captures biologically more homogenous groups and has a higher power for predicting tumor recurrence than the current WHO classification. The approach presented here is highly useful for stratifying meningioma patients for observation or adjuvant treatment groups. We consider methylation-based tumor classification highly relevant for the future diagnosis and treatment of meningioma.
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Research in context
Evidence before this study Meningiomas, the most frequent primary intracranial tumors, are diagnosed and graded according to the WHO classification of brain tumors. The recent update of this classification in 2016 has implemented molecular markers for several brain tumor entities.
However, there are still no established prognostic molecular markers for meningioma. Meningioma diagnostics is still based on purely histological criteria which are prone to a high inter-observer and sampling bias. Thus, the relevance of the current grading system for clinical decision making is heavily debated.
Previous work by several groups, including ours, has shown that DNA methylation signatures are specific for tumor entities. Importantly, DNA methylation profiling can identify biologically and clinically relevant subgroups among histologically indiscernible cases. Here, we employed this concept for the classification of meningiomas. A search in PubMed on October 21 2016 did not identify articles which used high-resolution DNA methylation profiling for identification of clinically relevant subgroups across all subtypes and grades of meningioma.
Added value of this study
We demonstrate that classification of meningiomas based on DNA methylation profiling is more powerful in predicting the clinical behavior than the current WHO classification and grading system. Our findings on a discovery series were confirmed on an independent validation series. Most notably, the novel approach was capable of identifying patients at high risk of rapid recurrence which were expected to have benign tumors based on WHO grading. Likewise, a considerable fraction of patients with the histological diagnosis of a higher grade meningioma -fostering the consideration of adjuvant treatment -but no recurrence could upfront be identified as low risk by DNA methylation profiling.
Implications of all the available evidence
Our data demonstrate that meningioma patients can be more accurately stratified for tumor behavior by DNA methylation profiling than by the current WHO classification. This greatly improves the basis for clinical decision making for or against additional therapy after surgery. We expect epigenetic profiling to be included into the diagnostic routine and implemented into upcoming updates of the WHO classification for brain tumors.
Introduction
The meninges exert a protective function for the entire central nervous system (CNS). During development, their precursor cells emerge from mesodermal structures and the neural crest, actively contributing to the differentiation of the brain [1] [2] [3] . However, meningeal cells may transform to initiate tumors. These meningiomas are the most frequent primary intra-cranial and spinal tumors 4 . While 80 % of meningiomas show a benign clinical behavior and can be cured by resection alone, about 20 % recur and need additional treatment such as repeated surgery, irradiation, and systemic chemotherapy 4, 5 . Histopathological evaluation aims at the identification of cases at risk for recurrence. The histological differentiation into subtypes initially dates back to the 19 th century.
Later, in a first internationally recognized classification approach in 1928, Bailey and Cushing distinguished meningothelial, fibroblastic, and angiomatous subtypes 6 , and to this day, allocation to subtype is based solely on histological findings. The current WHO classification recognizes 15
subtypes and three grades of malignancy 4 , but some of the diagnostic criteria are vaguely defined and subject to a high inter-observer bias, indicating the need for more reliable markers 5, 7 .
For various other CNS tumors, molecular profiling has identified distinct subtypes with characteristic aberrations. Many of these correlate with prognosis or provide targets for treatment, and therefore support clinical decision making, e.g. epigenetic subgroups in medulloblastoma [8] [9] [10] and ependymoma 11 , or isocitrate dehydrogenase (IDH) status in diffuse glioma [12] [13] [14] . Recent studies identified telomerase reverse transcriptase (TERT) promoter mutations in a small subset of meningiomas to be associated with higher risk of recurrence and shorter time to progression 15, 16 , and four large exome-sequencing efforts focusing on WHO grade I meningiomas have identified recurrently mutated genes beyond the long-known association with NF2 [17] [18] [19] [20] . Yet, these findings cover only a fraction of meningiomas and have not all been thoroughly tested for their prognostic relevance. In this study, we aimed at a comprehensive characterization of the entire molecular genetic landscape of meningioma in order to identify biologically and clinically relevant subgroups that refine the current classification scheme.
Results
DNA methylation analysis identifies six distinct methylation classes of meningioma
We generated genome-wide DNA methylation profiles from a discovery cohort of 497 meningiomas (Suppl. 
MC predict clinical course with higher accuracy than WHO grading
The wide spectrum of clinical behavior among WHO grade I and II meningiomas points towards the limited prognostic power of the current classification, particularly at the border between grade I and II. As a result, the basing of decisions about radiotherapy on the current grading scheme is heavily debated 5 . Thus, we correlated meningioma MCs with progression-free survival (PFS) to evaluate their potential for predicting outcome compared to WHO grading ( Fig. 2A, B) . We further combined
MCs exhibiting virtually identical benign (MC ben-1, MC ben-2, MC ben-3) or intermediate (MC int-A,
MC int-B) outcome into combined MCs (Fig. 2C ). Classification by individual and combined MCs demonstrates more precise prognostication than by WHO grading (Fig. 2D , Brier prediction test, p <0·01). These findings were confirmed in 140 meningiomas from an independent validation cohort (Suppl. Fig 3A, Table 2 ). However, combined MCs delineate subgroups with significantly distinct prognosis within all WHO grades (Fig. 3C ), demonstrating the benefit of MC-based grading for patients and the potential to significantly reduce under-or overtreatment.
Methylation classes are associated with distinct driver mutations and copy-number-alterations
We next sequenced 304 meningiomas with sufficient material available using a custom hybridcapture next-generation sequencing (NGS) panel dedicated to 40 genes previously reported to be mutant in meningioma (Suppl. Table 1 ), based on our recently established custom NGS approach for routine brain tumor diagnostics 21 . Known recurrent mutations (most frequently NF2, followed by TRAF7 and AKT1) were significantly enriched in certain MCs (Suppl. Table 3 Representative cases with sufficient material available of all MCs underwent RNA-sequencing which identified differentially upregulated genes and pathways (Suppl. Fig. 4 ).
Methylation classes and WHO subtypes, localization, and gender
Examining the distribution of histological subtypes, which currently determine grading, across MCs revealed which histological subtypes the MCs are composed of and, conversely, to which MC the samples of a respective subtype are assigned (Fig. 5) . The rare lymphoplasmacyte-rich meningioma (WHO grade I) was not assessed due to the overwhelming dominance of constitutional (non-tumor) DNA in these samples. In general, two patterns were observed: Either a given MC was strongly associated with a small set of or even single histological subtypes, or samples of a particular MC or subtype were widely spread across all corresponding variants. MC ben-1 comprised the majority of fibroblastic meningiomas and is also enriched for psammomatous meningioma. The most frequent localizations for all subgroups were the frontal and central convexity, except for MC ben-2 (Fig 6) . For the latter, basal localization was common, in line with the high occurrence of AKT1 and SMO mutations in this MC which are known to be enriched in this location 19, 22 .
Interestingly, all MC mal cases were located at the convexity. In contrast, none of the basal tumors were allotted to MC mal, including four intraventricular and ten spinal meningiomas that were all assigned to intermediate or benign MCs. Age distribution was equal throughout all MCs. In terms of gender, we observed a predominance of male patients in MC mal, while all other MCs mainly comprised female patients (Fig 6) .
Discussion
The 15 subtypes of meningioma included in the current WHO classification have evolved over decades. The major aim of introducing this variety of subgroups was to cover the whole histological spectrum of meningioma and to avoid misclassification of tumors mimicking other entities. For example, meningeal tumors with chordoid or rhabdoid cytology may initially raise suspicion of a chordoma or rhabdoid tumor but not point towards meningioma. Therefore, particular subtypes with these features were introduced into the classification in order to draw attention to the morphologic diversity of meningioma. In addition, some cytological features have been reported to be associated with distinct outcome. Although this was based on small series, it prompted allotment of distinct WHO grades to specific meningioma subtypes. However, this approach has been increasingly questioned due to suboptimal inter-observer reproducibility and limited prognostic effect of the histological criteria of higher grade 7, 23, 24 , most recently in a large Radiation Therapy Oncology Group 
Distinct methylation profiles suggest different development
Beyond the identification of clinically relevant groups and the basis for a novel classification, our dataset might provide insight into the development of meningioma. This has previously been shown for other entities: Four variants of medulloblastoma, distinguishable by their DNA methylation patterns, were shown to arise from different precursor cell populations 8, [25] [26] [27] , and exhibit very different clinical characteristics and therapy needs. Our data indicate that the spectrum of meningiomas is divided into two major molecularly highly distinct Groups (A and B, Fig. 1 ). This 
Methylation-based versus WHO subgrouping versus other molecular markers
Extensive whole exome or -genome sequencing has provided a large body of information on the mutational landscape of meningioma [17] [18] [19] [20] . Four distinct meningioma mutational subgroups have been proposed, defined by mutations either in NF2, TRAF7, the hedgehog pathway, or POLR2A TERT promoter mutations with unfavorable course may allow for mutation-based risk assessment in these subgroups, the current inability to stratify NF2-mutated meningiomas for other mutational events associated with clinical outcome is a major obstacle for a classification and grading system based on mutational profiling alone.
Similarly strong limitations apply to approaches based on copy-number-profiles: They leverage the accumulation of aberrations during progression but are not capable of predicting the behavior upfront. The current dataset attributes the highest prognostic power to methylome-based subgrouping, which proves to be superior to WHO classification (Fig. 2, 3) , while an exclusively mutation-based subgrouping for the full spectrum of meningioma is not available.
An integrated diagnosis for meningioma evaluation
The WHO 2016 revision of the classification for CNS tumors supports the concept of an integrated diagnosis. It relies on a multilayered approach combining data from histology, molecular genetic analyses, and clinical findings 4, 28, 29 . Adopting this WHO approach to the diagnosis of meningioma, the morphological layer corresponds to the current diagnostic standard, i.e. diagnosing the 15 WHO meningioma subtypes and grading according to the morphological scheme. In the absence of molecular analyses the morphological diagnosis should be suffixed with NOS (not otherwise Sahm et al., p. 12 specified), as agreed for parenchymal brain tumors without molecular workup 4 . The molecular diagnostic layer may contain elements such as DNA methylation and/or mutation analyses.
Mutational data may enable inferring the MC for a subset within the MC ben-2, e.g. for AKT1 mutant cases, but not in every instance. With methylation analysis performed, one of the six MCs can be diagnosed. If the MC is identified, this results in a significantly more powerful prediction of the clinical course. This corresponds to the current approach in other entities, e.g. ependymoma and medulloblastoma, for which methylation profiling has proven to be more relevant than histological grading 4, 11 . Based on the data presented here, the integrated diagnosis of meningioma will also highlight the prognostic impact of MCs, but in addition refer to the morphological subtype identified in histological examination.
Collectively, the dataset and accompanying classification scheme proposed here advances meningioma diagnostics from histology into an integrated profiling with higher accuracy of risk assessment for individual patients. 
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Materials and Methods Samples
Samples with clinical data were retrospectively collected from the Dept. 
Methylation analysis, copy-number analysis
Unsupervised clustering of the 450k data of the discovery and the EPIC 850k data of the validation cohort was performed as previously described (see Supplementary Materials and Methods for references) based on Euclidian distance and Ward's linkage method. For the clustering probes with a standard deviation greater 0.2 across all samples were selected. The methylation probes were reordered by hierarchical clustering using Euclidean distance and complete linkage.
Copy-number aberrations were inferred from methylation array data using the R/Bioconductor package conumee.
Cohort-wide copy number analysis in MCs
Methylation-class wide relative copy-number assessment was performed based on 450k data by a proprietary algorithm and controlled by manual inspection of the conumee-based copy-numberprofiles (Stichel et al., in preparation).
Panel and RNA sequencing
Panel sequencing for genes reported to be mutant in meningioma (Suppl. Table 1 ) was performed applying a custom hybrid-capture approach (Agilent) as described before. RNA libraries were generated with TruSeq RNA Access (Illumina) applying manufacturer supplied protocols. Sequencing was performed on a NextSeq 500 (Illumina).
Statistical analysis of clinical parameters
Distribution of survival times was estimated by the method of Kaplan and Meier and compared between groups with the log-rank test. Hazard ratios including 95% confidence intervals based on Cox regression models were calculated. For the multivariable Cox regression model, imputations of missing covariate values was done applying the multivariate imputations using chained equations (mice) algorithm with 100 imputation runs. Hazard ratio for age is given per 10 year increment.
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